Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma (TAMER)
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
A PHASE2 clinical study on Scleroderma, this trial is completed. The trial is conducted by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and has accumulated 11 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Sep 2020 — Nov 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Robyn T. Domsic, MD, MPH
For direct contact, visit the study record on ClinicalTrials.gov .